Hence, the selective target of myeloid cells-derived Siglec-15-mediated immune suppression can improve the therapeutic efficacy of PD-1/B7-H1 blockade strategy which then represents acquired resistance in the aspect of several human cancers [76, 77]. Here, CD274 is linked to cancer.